Aytu Biopharma Inc
NASDAQ:AYTU
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Aytu Biopharma Inc
NASDAQ:AYTU
|
22.8m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
995.7B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
573.2B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.7B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
231.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
217.3B GBP |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.7B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Aytu Biopharma Inc
Glance View
Aytu Biopharma, Inc. is a specialty pharmaceutical company, which focuses on identifying, acquiring, and commercializing novel products. The company is headquartered in Englewood, Colorado and currently employs 175 full-time employees. The company went IPO on 2017-10-20. The firm markets a portfolio of prescription products addressing primary care and pediatric markets. The firm's primary prescription products treat attention deficit hyperactivity disorder (ADHD) and other common pediatric conditions. The company markets ADHD products Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets, Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets, and Adzenys-ER (amphetamine) extended-release oral suspension. The firm's other pediatric products include Karbinal ER (carbinoxamine maleate), an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines containing combinations of fluoride and vitamins in formulations for infants and children with fluoride deficiency.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Aytu Biopharma Inc is -20.5%, which is below its 3-year median of -16.5%.
Over the last 3 years, Aytu Biopharma Inc’s Net Margin has increased from -79.7% to -20.5%. During this period, it reached a low of -79.7% on Sep 30, 2022 and a high of 2.4% on Mar 31, 2025.
